Interview with CEO of BioSig Technologies (BSGM): Seeking Better Outcomes for Patients with Complex Arrhythmias

Seeking Better Outcomes for Patients with Complex Arrhythmias

NEW YORK, NY / ACCESSWIRE / April 14, 2016 / President and CEO of BioSig Technologies Inc. (BSGM), Greg Cash, discusses the Company’s PURE EP system, a medical device in late stage development which addresses a strong need in the high growth electrophysiology market.

The Company’s PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP system is an add-on device designed to dramatically improve ECG signal quality of existing electrophysiology recorders from companies like Boston Scientific (BSX), GE Healthcare (GE), and St. Jude Medical (SJT).

Markedly improved ECG signal quality delivered with the BioSig patented PURE EP system during electrophysiology studies and catheter ablations is expected to reduce procedure times while also improving diagnostic clarity, ablation success rates, and patient outcomes.

The interview includes:

– a discussion of how the PURE EP system can substantially improve signal quality in ECG recording systems from Boston Scientific, GE Healthcare, and St. Jude Medical as an add-on device
– preclinical studies of the PURE EP system at Mayo Clinic
– a timeline for commercialization of the PURE EP system
– plans to uplist BSGM shares to the NASDAQ exchange this year

Read the interview by clicking here now.

About BioSig Technologies Inc.

BioSig Technologies, Inc., a development stage medical device company, engages in developing technology platform to minimize noise and artifacts from cardiac recordings during electrophysiology studies and ablation. Its product under development includes PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP system, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and ablation procedures. The company is also developing a library of software tools that are designed to be configured to fit the needs of electrophysiologists in various settings and/or for arrhythmia treatments. BioSig Technologies, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.

About MicrocapResearch.com

Launched in 2014, MicrocapResearch.com is an investment research service featuring small and microcap stocks that have key drivers the publishers believe will drive share prices higher in the near term. Our microcap picks averaged a fully documented 100.6% gain during 2015 measured from the date prior to our reports, to the post report high.

The publishers of MicrocapResearch.com are not registered as investment advisors in any jurisdiction. Investing in stocks, particularly small and microcap stocks, is highly speculative. Never invest in any stock unless you can afford to lose your entire investment and consult your investment professional before making any investment decision. Please see applicable disclosures and site-wide disclaimer at MicrocapResearch.com.

CONTACT: Inquiries@MicrocapResearch.com

SOURCE: MicrocapResearch.com

ReleaseID: 438778